149 13th Street – 6010
Charlestown, MA 02129
Mario Luca Suvà, MD, PhD
Associate Professor of Pathology
Massachusetts General Hospital
Associate Molecular Pathologist
Massachusetts General Hospital
Broad Institute of MIT and Harvard
Co-Leader, Neuro-Oncology Program, DF/HCC
Co-Leader, Cancer Program, Harvard Stem Cell Institute
Center for Cancer Research
Explore the Suvà Lab
The Suvà laboratory develops and applies single-cell genomic technologies and advanced computational analyses to dissect the biology of brain tumors, in particular adult and pediatric gliomas. We study clinical samples at single-cell resolution and establish genetically and epigenetically faithful cellular models directly from patient tumors. We model how brain cancer cells exploit their plasticity to establish phenotypically distinct populations of cells, with a focus on programs governing glioma stem cells. We seek to redefine tumor cell lineages and stem cell programs across all subtypes of gliomas, and to leverage the information for renewed therapeutics. In close collaborations, the laboratory additionally leverages single-cell genomics to dissect the immune system of gliomas and to chart the cellular programs in sarcomas.
Cell state heterogeneity is an important disease hallmark of both IDH-mutant glioma and IDH-wildtype glioblastoma, with genetic clonal diversity intermingled with neurodevelopmental trajectories. Stemnessto- differentiation diversity is central to the glioma stem cell (GSC) model, which posits that stem-like cells are uniquely capable of self-renewal, tumor propagation and preferential resistance to therapy. Recent single-cell RNA-sequencing efforts in glioma led by my laboratory provided high-resolution mapping of cell state diversity and offered additional granularity to the GSC model by revealing multiple transcriptionally-defined cell states related to neurodevelopmental cell types. Yet, while cellular states can be precisely delineated by scRNAseq, glioma cell state heritability and transition dynamics are not defined, and the epigenetic underpinning of glioma cellular states is still largely unknown. Equally unaddressed are cellular cross-talks within the glioma ecosystem (e.g. cancer-immune interactions). In order to dissect those influences and obtain a comprehensive view of gliomas biology, my laboratory is leveraging joint capture of transcriptional, genetic, and epigenetic information (DNAme, chromatin accessibility) at the single-cell resolution to primary diffuse gliomas. Additionally, we integrate single-cell genomics of human tumors with mouse models, computational deconvolution of profiles from The Cancer Genome Atlas (TCGA) and functional experiments. Our approach offers a compelling framework to comprehensively dissect the glioma ecosystem, both at diagnosis and under therapeutic pressure.
Assessing Malignant Cells Heterogeneity at the Single-Cell Level in Gliomas
The Suvà Lab is performing large-scale single-cell RNA-seq analyses in IDH-mutant gliomas, histone H3-mutant midline gliomas, IDH-wildtype glioblastoma, and medulloblastoma to assess tumor cell lineages, stem cell programs and genetic heterogeneity at an unprecedented scale and depth. Our work in IDH-mutant gliomas highlighted a rare subpopulation of actively dividing stem/progenitor cells, solely responsible for fueling tumor growth in patients. Single cell profiling of H3K27- mutant pediatric gliomas highlighted specific vulnerabilities and revealed a differentiation block, maybe explaining the more aggressive nature of this cancer type. More recently, we provided a comprehensive model of glioblastoma biology that integrates single-cell expression programs, genetic composition and tumor subtypes (see figure). Our study of medulloblastoma single-cell programs provided clarifications on tumor histogenesis and classification. The lab is currently performing such single-cell analyses with constantly increased throughput, resolution and in broader clinical settings (e.g. rare entities, novel clinical trials). Overall, our goal is to identify both lineage-defined and somatically-altered therapeutic targets in brain cancer in both children and adults.
Dissecting the Ecosystem of Gliomas
The composition of the tumor microenvironment (TME) has an important impact on tumorigenesis and modulation of treatment responses. For example, gliomas contain substantial populations of microglia and macrophages, with putative immunosuppressive functions but whose precise programs remains uncharted at single-cell resolution. In addition, very little is known about the functional state of T cells in human gliomas. As is the case in diverse other conditions, the CNS may create a unique microenvironment that impacts T cell function by distinct mechanisms. The laboratory leverages single-cell analyses in clinical samples to dissect the functional programs of immune cells in gliomas that can be used to elucidate mechanisms relevant to immuno-oncology. We profile both dysfunctional T cells that express multiple inhibitory receptors and T cells that are functional based on expression of multiple genes required for T cell cytotoxicity. We find these modules to be distinct from observations in other types of tumors (such as melanoma), underscoring the necessity to perform these analyses directly in gliomas. By analyzing modules of co-expressed genes in subsets of T cells in patients with glioma we seek to shed light on mechanism of activation and exhaustion in patient tumors and to highlight candidate novel regulatory programs that can be exploited for therapeutics.
View a list of publications by researchers at the Suva Laboratory
Hara T†, Chanoch-Myers R†, Mathewson ND, Myskiw C, Fan J, Bussema L, Atta L, Eichhorn SW, Greenwald A, Kinker G,…Hunter T, Verma IM, Wucherpfennig KW, Regev A, Suvà ML*, Tirosh I*. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell. 2021 Jun 14;39(6):779-792.
Mathewson ND†, Ashenberg O†, Tirosh I†, Gritsch S†, Perez EM†, Marx S†, Jerby-Arnon L, Chanoch-Myers R, Hara T,…Louis DN, Ligon KL, Marson A, Chiocca EA, Reardon DA, Regev A*, Suvà ML*, Wucherpfennig KW*. Inhibitory CD161 Receptor Identified in Glioma-infiltrating T cells by Single Cell Analysis. Cell. 2021 Mar 4;184(5):1281-1298.
Neftel C†, Laffy J†, Filbin MG†, Hara T†, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez L, Gonzalez Castro LN, …, Louis DN, Regev A, Bernstein BE, Tirosh I*, Suvà ML*. An integrative model of cellular states, plasticity and genetics for glioblastoma. Cell. 2019 Aug 8;178(4):835-849.
Filbin MG†, Tirosh I†, Hovestadt V†, Shaw ML, Escalante LE, …, Getz G, Rozenblatt-Rosen O, Wucherpfennig KW, Louis DN, Monje M, Slavc I, Ligon KL, Golub TR, Regev A*, Bernstein BE*, Suvà ML* Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018 Apr 20;360(6386).
Venteicher AS†, Tirosh I†, Hebert C, Yizhak K, Neftel C, Filbin MG, Hovestadt V, ..., Cahill DP, Rozenblatt-Rosen O, Louis DN, Bernstein BE, Regev A*, Suvà ML*. Decoupling genetics, lineages and micro-environment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017 Mar 31; 55(6332).
Tirosh I†, Venteicher AS†, Hebert C, Escalante LE, Patel AP, Yizhak K, Fisher JM, ..., Rivera MN, Getz G, Rozenblatt-Rosen O, Cahill DP, Monje M, Bernstein BE, Louis DN, Regev A*, Suvà ML*. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature, 2016 Nov 10;539(7628).
Mario Luca Suvà, MD, PhDPrincipal Investigator
- Lilly Bussema, BS
- Sydney Dumont, BS
- Nicolas Druck, BS
- Yilin Fan, PhD
- Nick Gonzalez-Castro, MD, PhD
- Simon Gritsch, MD, PhD
- Toshiro Hara, PhD
- Alexander Jucht*
- Vamsi Mangena, PhD
- Chris Mount, MD, PhD
- Masashi Nomura, MD, PhD
- Liz Perez*
- Channing Pooley, BS
- Dana Silverbush, PhD
- Itay Tirosh, PhD
- Jun Zhong, BS
Center for Cancer Research
The scientific engine for discovery for the Mass General Cancer Center.
Support the Center for Cancer Research
When you support the Center for Cancer Research you are enabling discoveries that will lead to effective new weapons in the battle against cancer.
participated in Clinical Trials at the Mass General Cancer Center last year
This helped lead to new knowledge and breakthrough therapies.